A5050163070- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Cancer, Lipids, and Metabolism
- Gastric Cancer Management and Outcomes
- Cancer, Hypoxia, and Metabolism
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- T-cell and B-cell Immunology
- Cancer Immunotherapy and Biomarkers
- Mitochondrial Function and Pathology
- Cancer Cells and Metastasis
- Metabolism, Diabetes, and Cancer
- DNA Repair Mechanisms
Dartmouth College
2024-2025
Dartmouth Cancer Center
2024
Colby College
2023
Abstract Despite adjuvant treatment with endocrine therapies, estrogen receptor-positive (ER+) breast cancers recur in a significant proportion of patients. Recurrences are attributable to clinically undetectable endocrine-tolerant persister cancer cells that retain tumor-forming potential. Therefore, strategies targeting such may prevent recurrent disease. Using CRISPR-Cas9 genome-wide knockout screening ER+ cells, we identified survival mechanism involving metabolic reprogramming reliance...
<p>Suppl. Figure 6</p>
<p>Suppl. Figure 1</p>
<p>Suppl. Figure 4</p>
<p>Suppl. Figure 2</p>
<p>Suppl. Figure 5</p>
<p>Clinical study protocol (version 11October2021)</p>
<p>Suppl. Figure 8</p>
<p>L:egends for Suppl. Figs. 1-8</p>
<p>Suppl. Figure 3</p>
<div>Abstract<p>Despite adjuvant treatment with endocrine therapies, estrogen receptor–positive (ER<sup>+</sup>) breast cancers recur in a significant proportion of patients. Recurrences are attributable to clinically undetectable endocrine-tolerant persister cancer cells that retain tumor-forming potential. Therefore, strategies targeting such may prevent recurrent disease. Using CRISPR-Cas9 genome-wide knockout screening ER<sup>+</sup> cells, we...
<p>Suppl. Figure 7</p>
Overcoming immune suppression is a major barrier to eliciting potent CD8